Anika Therapeutics, Inc. (ANIK) Reports Q3 EPS of 22c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.22, vs. the analyst estimate of $0.11. Revenue for the quarter came in at $18.5 million versus the consensus estimate of $15.1 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
